Trevi Therapeutics, Inc.TRVINASDAQ
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+82.7%
Year-over-Year Change
Year-over-year free cash flow growth rate
3Y CAGR
+82.7%/yr
Quarterly compound
Percentile
P100
Near historical high
vs 3Y Ago
6.1x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 153.67% |
| Q3 2025 | -7.83% |
| Q2 2025 | 25.05% |
| Q1 2025 | -41.02% |
| Q4 2024 | -0.01% |
| Q3 2024 | -9.70% |
| Q2 2024 | 16.78% |
| Q1 2024 | -64.03% |
| Q4 2023 | 12.55% |
| Q3 2023 | 26.40% |
| Q2 2023 | -20.12% |
| Q1 2023 | -28.03% |
| Q4 2022 | 25.20% |
| Q3 2022 | -39.56% |
| Q2 2022 | 12.92% |
| Q1 2022 | -13.85% |
| Q4 2021 | 13.98% |
| Q3 2021 | 8.32% |
| Q2 2021 | -4.22% |
| Q1 2021 | 15.13% |
| Q4 2020 | -27.89% |
| Q3 2020 | 17.35% |
| Q2 2020 | -80.78% |
| Q1 2020 | 24.65% |
| Q4 2019 | 19.81% |
| Q3 2019 | -52.82% |
| Q2 2019 | -23.29% |
| Q1 2019 | 14.94% |
| Q4 2018 | -20.89% |
| Q3 2018 | 28.97% |
| Q2 2018 | -40.11% |
| Q1 2018 | -140785.14% |
| Q4 2017 | 0.00% |